Galderma SA’s monopoly on its brand-name acne treatment Differin Gel 0.3% went up in smoke on Wednesday, when the generic drug company Tolmar Inc. and its lawyers at McDermott Will & Emery persuaded the U.S. Court of Appeals for the Federal Circuit to invalidate Galderma’s patents.
*May exclude premium content
Already have an account? Sign In Now
Interested in customizing your subscription with Law.com All Access?
Contact our Sales Professionals at 1-855-808-4530 or send an email to email@example.com to learn more.